Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
In: GlobeNewswire, 2024-05-14
Zeitungsartikel
Zugriff:
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance [...]
Titel: |
Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
|
---|---|
Zeitschrift: | GlobeNewswire, 2024-05-14 |
Veröffentlichung: | 2024 |
Medientyp: | Zeitungsartikel |
Schlagwort: |
|
Sonstiges: |
|